Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
TAK evidence brief
What we can confirm
- BioSniper Score:
- 1.5 / 10
- Market Cap:
- $59.38B
- Next Catalyst:
- Phase2_Start · Mar 1, 2027
What it means
What to watch
Prepared research question
What matters most for TAK—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · TAK
Takeda Pharmaceutical Company Limited is a global R&D-driven biopharmaceutical company focused on discovering and delivering life-transforming treatments in gastrointestinal and inflammation, neuroscience, and oncology, with a growing rare disease and plasma-derived therapeutics portfolio [sec · filed 2026-06-17].
Key risk: Clinical and regulatory uncertainty
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Tracking 227 clinical trials · 1 catalyst for Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock).
Takeda Pharmaceutical Company Limited is a global R&D-driven biopharmaceutical company focused on discovering and delivering life-transforming treatments in gastrointestinal and inflammation, neuroscience, and oncology, with a growing rare disease and plasma-derived therapeutics portfolio [sec · filed 2026-06-17].
- Takeda is a global R&D-driven biopharmaceutical company focused on gastrointestinal and inflammation, neuroscience, and oncology [sec · filed 2026-06-17].
- As of fiscal year ending March 31, 2027, New Launches include EOHILIA, LIVTENCITY, ADZYNMA, FRUZAQLA, and QDENGA; Core In-Line Brands include ENTYVIO, GATTEX/REVESTIVE, TAKECAB/VOCINTI, TAKHZYRO, immunoglobulin products, albumin products, and ADCETRIS [sec · filed 2026-06-17].
- In the fiscal year ended March 31, 2026, Takeda submitted NDAs in the U.S. for oveporexton and rusfertide following successful Phase 3 clinical trials [sec · filed 2026-06-17].
- Takeda's R&D efforts focus on three core therapeutic areas: Gastrointestinal and Inflammation, Neuroscience, and Oncology [sec · filed 2026-06-17].
- In June 2026, Takeda presented results from pivotal studies showing oveporexton improved daily functioning and cognitive symptoms associated with narcolepsy type 1 [sec · filed 2026-06-17].
What works
- Takeda has a strong pipeline of new molecular entities (NMEs) representing potential best-in-class or first-in-class medicines across core therapeutic areas [sec · filed 2026-06-17].
- The company has successfully submitted NDAs for oveporexton and rusfertide following positive Phase 3 results, indicating progress toward new product launches [sec · filed 2026-06-17].
- Takeda is embracing data and digital technologies, including AI, to improve innovation quality and accelerate execution in drug discovery [sec · filed 2026-06-17].
What to weigh
- Takeda's pipeline success depends on clinical trial results, regulatory approvals, and market conditions, which are inherently uncertain [sec · filed 2026-06-17].
- The company faces external pressures in the global healthcare environment that may impact operations and growth [sec · filed 2026-06-17].
- Takeda's growth is heavily reliant on a limited number of key products and business areas, creating concentration risk [sec · filed 2026-06-17].
From the filings
Quoted directly from source documents.
Takeda is a global R&D-driven biopharmaceutical company.
“We are a global R&D-driven biopharmaceutical company focused on discovering and delivering life-transforming treatments in our core therapeutic areas of gastrointestinal and inflammation, neuroscience and oncology,”
SEC filings · June 17, 2026
Takeda submitted NDAs for oveporexton and rusfertide after successful Phase 3 trials.
“In the fiscal year ended March 31, 2026, we submitted New Drug Applications ("NDAs") in the U.S. for oveporexton and rusfertide following successful Phase 3 clinic”
SEC filings · June 17, 2026
Oveporexton improved daily functioning and cognitive symptoms in NT1 patients.
“oveporexton significantly improved daily functioning at week 12 compared to placebo (p<0.001) across the six domains of the Functional Impacts of Narcolepsy Instrument (FINI). Oveporexton improved cognitive symptoms associated with NT1 compared to placebo”
SEC filings · June 17, 2026
Takeda is integrating AI into drug discovery.
“We seek to achieve a foundational shift that embeds AI into every stage of drug discovery, redesigning workflows to include automated, data-driven, predictive processes that accelerate innovation.”
SEC filings · June 17, 2026
Catalyst timeline
- 2027-03-01 · Phase2_Start: A Phase 2 Open-Label Trial to Evaluate the Efficacy and Safety of the Hepcidin Mimetic Rusfertide (TAK-121) in Chinese Patients With Polycythemia Vera — This trial initiation will provide early efficacy and safety data for rusfertide in a Chinese patient population, potentially supporting future regulatory submissions in the region.
Risks & what to watch (3)›
Key risks
- Clinical and regulatory uncertainty — Pipeline success depends on clinical trial results, regulatory approvals, and market conditions, which are inherently uncertain [sec · filed 2026-06-17].
- Concentration on key products — Growth is heavily reliant on a limited number of key products and business areas, creating concentration risk [sec · filed 2026-06-17].
- External healthcare pressures — External pressures in the global healthcare environment may impact operations and growth [sec · filed 2026-06-17].
What to watch
- Regulatory decisions on oveporexton and rusfertide NDAs submitted in fiscal year ended March 31, 2026 [sec · filed 2026-06-17].
- Launch progress of new products such as ENTYVIO Pen and subcutaneous formulations [sec · filed 2026-06-17].
- Phase 2 trial results for rusfertide (TAK-121) in Chinese patients with polycythemia vera, expected to start in 2027 [catalyst].
- Adoption and impact of AI and digital technologies on drug discovery and development [sec · filed 2026-06-17].
Sources: SEC filings · Generated October 12, 2026 · How we verify sources →
Run Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
Pipeline inputs are unavailable for this score. It uses only the available signals shown below.
Cash runway data unavailable
Financial health data unavailable
No tracked pipeline phase
No tracked pipeline candidates
1 upcoming, next in ~138d
0 buys · 18 sells (180d)
Catalysts
Regulatory
Financials
Short Interest
as of May 1, 2026- % of float
- 0.1%
- Days to cover
- 1.5
- Shares short
- 4,734,092
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
TAK short interestGovernance
Frequently asked questions
What is the AI investment thesis for Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)?
Takeda Pharmaceutical Company Limited is a global R&D-driven biopharmaceutical company focused on discovering and delivering life-transforming treatments in gastrointestinal and inflammation, neuroscience, and oncology, with a growing rare disease and plasma-derived therapeutics portfolio [sec · filed 2026-06-17].
What is Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)'s next catalyst?
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)'s next tracked catalyst is a Phase2_Start event — "Phase2_Start: A Phase 2 Open-Label Trial to Evaluate the Efficacy and Safety of the Hepcidin Mimetic Rusfertide (TAK-121) in Chinese Patients With Polycythemia Vera" — expected March 1, 2027.
Who is the CEO of Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)?
Ms. Julie Kim is the chief executive officer of Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK).
Where is Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) headquartered?
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) is headquartered in Chuo, Japan.
What therapeutic areas does Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) focus on?
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) develops therapies across Oncology, Rare Disease, Neurology, Immunology, Cardiovascular, Infectious Disease, Metabolic, Respiratory, Pain, Dermatology, Hematology, Nephrology, Gastroenterology, Endocrinology, Reproductive, Psychiatry.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.